

Learn about common and serious Eliquis side effects, who's most at risk, how to manage them, and when to seek emergency medical help.
Eliquis (Apixaban) is one of the most widely prescribed blood thinners in the United States. It's used to prevent strokes in people with atrial fibrillation, treat blood clots, and reduce the risk of clots after hip or knee replacement surgery. Like all medications, Eliquis comes with potential side effects — some minor, some serious.
This guide breaks down the most common and serious side effects of Eliquis based on FDA labeling, so you know what to watch for and when to call your doctor.
Eliquis is a direct oral anticoagulant (DOAC) that works by blocking Factor Xa, a key protein in the blood clotting process. It's made by Bristol-Myers Squibb and Pfizer and is taken as a tablet twice daily. To learn more about how this medication works, see our guide on how Eliquis works.
The most frequently reported side effects of Eliquis are related to its blood-thinning action. These are usually mild and may improve as your body adjusts:
These side effects affect a relatively small percentage of patients in clinical trials. Most people taking Eliquis tolerate it well.
Because Eliquis prevents blood from clotting normally, the most serious risk is uncontrolled bleeding. Call your doctor or go to the emergency room right away if you experience:
Eliquis carries two FDA boxed warnings — the most serious type of safety alert:
Some people may be at higher risk for side effects:
Elderly patients may have a higher risk of bleeding. Doctors often prescribe the lower 2.5 mg dose for patients aged 80 or older who also have low body weight or reduced kidney function.
While Eliquis doesn't require dose adjustment for mild-to-moderate kidney impairment, patients with severe kidney disease need careful monitoring. Your doctor may check your kidney function with blood tests before and during treatment.
Taking Eliquis with other anticoagulants (like Warfarin or Heparin), antiplatelet drugs (like Aspirin or Clopidogrel), or NSAIDs (like Ibuprofen or Naproxen) significantly increases bleeding risk. Always tell your doctor about all medications you're taking. For a full list, see our guide on Eliquis drug interactions.
People with severe liver problems should use Eliquis with caution. Your doctor will evaluate whether it's safe for you.
If you're experiencing mild side effects, here are some practical tips:
Never stop taking Eliquis on your own because of side effects. Stopping suddenly can put you at risk for stroke or blood clots. Always talk to your doctor first about any concerns.
Unlike Pradaxa (Dabigatran), which has a specific reversal agent called Praxbind, Eliquis does not have a dedicated reversal drug approved by the FDA. In emergency bleeding situations, doctors may use Andexxa (Andexanet Alfa), a Factor Xa reversal agent, or other supportive treatments. This is one reason it's important to keep your doctor informed and seek emergency care for serious bleeding.
Most people take Eliquis without experiencing serious problems. The most common side effects — bruising, minor bleeding, and nausea — are manageable and often improve over time. But because Eliquis is a blood thinner, it's critical to know the warning signs of serious bleeding and to contact your doctor right away if something doesn't feel right.
If you're looking for more information about Eliquis, check out our guides on what Eliquis is and how it's used or how to save money on your prescription. And if you need help finding Eliquis in stock, Medfinder can help you locate a pharmacy near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.